Literature DB >> 9496247

Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.

J Schirra1, P Leicht, P Hildebrand, C Beglinger, R Arnold, B Göke, M Katschinski.   

Abstract

Twelve patients with non-insulin dependent diabetes mellitus (NIDDM) under secondary failure to sulfonylureas were studied to evaluate the effects of subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) on (a) the gastric emptying pattern of a solid meal (250 kcal) and (b) the glycemic and endocrine responses to this solid meal and an oral glucose tolerance test (OGTT, 300 kcal). 0.5 nmol/kg of GLP-1 or placebo were subcutaneously injected 20 min after meal ingestion. GLP-1 modified the pattern of gastric emptying by prolonging the time to reach maximal emptying velocity (lag period) which was followed by an acceleration in the post-lag period. The maximal emptying velocity and the emptying half-time remained unaltered. With both meals, GLP-1 diminished the postprandial glucose peak, and reduced the glycemic response during the first two postprandial hours by 54.5% (solid meal) and 32.7% (OGTT) (P < 0.05). GLP-1 markedly stimulated insulin secretion with an effect lasting for 105 min (solid meal) or 150 min (OGTT). The postprandial increase of plasma glucagon was abolished by GLP-1. GLP-1 diminished the postprandial release of pancreatic polypeptide. The initial and transient delay of gastric emptying, the enhancement of postprandial insulin release, and the inhibition of postprandial glucagon release were independent determinants (P < 0.002) of the postprandial glucose response after subcutaneous GLP-1. An inhibition of efferent vagal activity may contribute to the inhibitory effect of GLP-1 on gastric emptying.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496247     DOI: 10.1677/joe.0.1560177

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  17 in total

1.  Diabetes-related alterations in the enteric nervous system and its microenvironment.

Authors:  Mária Bagyánszki; Nikolett Bódi
Journal:  World J Diabetes       Date:  2012-05-15

2.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

3.  Effect of Gongronema latifolium on gastric emptying in healthy dogs.

Authors:  Sylvester O Ogbu; Kenneth K Agwu; Isaac U Asuzu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

4.  Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Marie Langmach Wegeberg; Christian Stevns Hansen; Adam D Farmer; Jesper Scott Karmisholt; Asbjorn M Drewes; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  United European Gastroenterol J       Date:  2020-05-09       Impact factor: 4.623

Review 5.  Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.

Authors:  Magnus Halland; Adil E Bharucha
Journal:  Clin Gastroenterol Hepatol       Date:  2015-12-21       Impact factor: 11.382

6.  Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.

Authors:  J Schirra; M Nicolaus; R Roggel; M Katschinski; M Storr; H J Woerle; B Göke
Journal:  Gut       Date:  2005-06-28       Impact factor: 23.059

7.  Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.

Authors:  J Schirra; P Houck; U Wank; R Arnold; B Göke; M Katschinski
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

8.  Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans.

Authors:  J Schirra; U Wank; R Arnold; B Göke; M Katschinski
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

9.  Entero-insular axis and postprandial insulin differences in African American and European American children.

Authors:  Paul B Higgins; José R Férnández; W Timothy Garvey; Wesley M Granger; Barbara A Gower
Journal:  Am J Clin Nutr       Date:  2008-11       Impact factor: 7.045

Review 10.  Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.

Authors:  George G Holz; Oleg G Chepurny
Journal:  Curr Med Chem       Date:  2003-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.